JPWO2023140269A5 - - Google Patents

Info

Publication number
JPWO2023140269A5
JPWO2023140269A5 JP2024543040A JP2024543040A JPWO2023140269A5 JP WO2023140269 A5 JPWO2023140269 A5 JP WO2023140269A5 JP 2024543040 A JP2024543040 A JP 2024543040A JP 2024543040 A JP2024543040 A JP 2024543040A JP WO2023140269 A5 JPWO2023140269 A5 JP WO2023140269A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
satralizumab
subject
administered
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502891A5 (https=
JP2025502891A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2023/001270 external-priority patent/WO2023140269A1/en
Publication of JP2025502891A publication Critical patent/JP2025502891A/ja
Publication of JP2025502891A5 publication Critical patent/JP2025502891A5/ja
Publication of JPWO2023140269A5 publication Critical patent/JPWO2023140269A5/ja
Pending legal-status Critical Current

Links

JP2024543040A 2022-01-19 2023-01-18 自己免疫性脳炎のサトラリズマブによる治療 Pending JP2025502891A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263300893P 2022-01-19 2022-01-19
US63/300,893 2022-01-19
PCT/JP2023/001270 WO2023140269A1 (en) 2022-01-19 2023-01-18 Treatment of autoimmune encephalitis with satralizumab

Publications (3)

Publication Number Publication Date
JP2025502891A JP2025502891A (ja) 2025-01-28
JP2025502891A5 JP2025502891A5 (https=) 2026-01-14
JPWO2023140269A5 true JPWO2023140269A5 (https=) 2026-01-14

Family

ID=87348849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543040A Pending JP2025502891A (ja) 2022-01-19 2023-01-18 自己免疫性脳炎のサトラリズマブによる治療

Country Status (11)

Country Link
US (1) US20250127891A1 (https=)
EP (1) EP4466018A4 (https=)
JP (1) JP2025502891A (https=)
KR (1) KR20240145472A (https=)
CN (1) CN118900699A (https=)
AU (1) AU2023209259A1 (https=)
CA (1) CA3243067A1 (https=)
IL (1) IL314213A (https=)
MX (1) MX2024008835A (https=)
TW (1) TW202337495A (https=)
WO (1) WO2023140269A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
IL287220B2 (en) 2019-04-17 2026-03-01 Univ Hiroshima A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor
AU2021278562A1 (en) 2020-05-29 2022-12-01 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206775B1 (en) 2007-09-26 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US20120039840A1 (en) 2008-12-02 2012-02-16 Hunter Christopher A Use of IL-27-P28 to antagonize IL-6 mediated signaling
JP6130983B2 (ja) 2015-02-27 2017-05-17 中外製薬株式会社 Ｉｌ−６関連疾患治療用組成物
JPWO2020202839A1 (https=) * 2019-03-29 2020-10-08

Similar Documents

Publication Publication Date Title
Egan et al. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine
Sherer et al. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases
JPWO2020249687A5 (https=)
Markman et al. An effective and more convenient drug regimen for prophylaxis gainst paclitaxel-associated hypersensitivity reactions
Collet et al. Juvenile dermatomyositis: treatment with intravenous gammaglobulin
JPWO2023140269A5 (https=)
IL320562A (en) Cancer treatment methods
Tumani Corticosteroids and plasma exchange in multiple sclerosis
Rommer et al. Repurposing multiple sclerosis drugs: a review of studies in neurological and psychiatric conditions
Soueidan et al. Treatment of autoimmune neuromuscular diseases with high-dose intravenous immune globulin
Cherin et al. Indications for intravenous gammaglobulin therapy in inflammatory myopathies
Weiner et al. Therapy for multiple sclerosis
Trobe High-dose corticosteroid regimen retards development of multiple sclerosis in optic neuritis treatment trial
Sandborn Strategies targeting tumor necrosis factor in Crohn’s disease
JPWO2023095510A5 (https=)
US20040147433A1 (en) Neuroimmunophilins for selective neuronal radioprotection
AU766095B2 (en) Neuroimmunophilins for selective neuronal radioprotection
Baert et al. Immunomodulator therapy of inflammatory bowel disease.
JPWO2022198192A5 (https=)
CN108014337A (zh) 一种用于治疗眼自身免疫性葡萄膜炎的药物组合物
Giacobbe et al. Treatment-resistant CIDP in an IgG Tubulin Autoantibody Positive Patient: case report and review of the literature
Gibaldi et al. Steady-state concentrations of drugs with short half-lives when administered in oral sustained release formulations
Marcocci et al. Immunosuppressive management of Graves’ ophthalmopathy
Sethi et al. Antidote or poison: A case of anaphylactic shock after intra-articular corticosteroid injection
van Riel et al. Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis